Search Results

You are looking at 21 - 30 of 286 items for :

  • "risk assessment" x
  • Refine by Access: All x
Clear All
Full access

Presenters: Robert Pilarski, Jennifer M. Weiss, Susan M. Domchek, and Moderated by Tuya Pal

in approximately 2% of the general population, and risk estimates for colorectal cancer are conflicting (no increased risk to > twofold risk) 1 , 2 The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal for managing individuals

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee, and Anaadriana Zakarija

diagnosis, prevention, and treatment of VTE in cancer patients and provide recommendations for patient care based on clinical research and experience in this field. VTE Risk Assessment in Patients With Cancer Many risk factors for VTE are common to

Full access

Stanford Hospital and Clinics

Recent advances in molecular genetics have identified several genes associated with inherited susceptibility to cancer and have provided a means to begin identifying individuals and families with an increased risk of cancer. This rapid expansion of knowledge about cancer genetics has implications for all aspects of cancer management, including prevention, screening, and treatment. These guidelines specifically address hereditary breast/ovarian cancer syndrome (HBOC), Li-Fraumeni syndrome, and Cowden syndrome. These guidelines were developed understanding that much of our knowledge of how the rapidly emerging field of molecular genetics can be applied clinically is preliminary and that flexibility is needed when applying these guidelines to individual families.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Breast Cancer Screening include a risk assessment and intervention for breast cancer risk reduction, but risk assessment is not well incorporated in clinical practice. The Athena Breast Health Network is a University of California collaborative network

Full access

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov

with her breasts), physical examination, risk assessment, screening mammography, and, in selected cases, screening MRI. A diagnostic breast evaluation differs from breast screening in that it is used to evaluate an existing problem (e.g., dominant

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward

-07-10 ©2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. Risk Assessment Estimation of breast cancer risk

Full access

Christina Rybak and Michael J. Hall

Colorectal cancer (CRC) risk assessment involves evaluation of an individual's personal and family history for characteristics of an inherited susceptibility to develop CRC. These characteristics include early age at diagnosis, multiple primary

Full access

Douglas Arenberg and Ella A. Kazerooni

This article summarizes what is known about the best practices of lung cancer screening and provides suggestions for the proper structure for institutions considering offering lung cancer screening services. Important points of emphasis include the need to confine screening to patients at highest risk, the presence of multidisciplinary teams capable of managing the high number of false-positive findings, the need for additional research on biomarkers and risk models for lung cancer, and the currently unknown cost-effectiveness of lung cancer screening on a societal level.

Full access

Kenneth Offit

Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast and Ovarian 1 and Colorectal 2 provide suggestions for mutation carriers identified by panel tests. Hereditary Cancers Current estimates are that the hereditary burden of

Full access

NCCN Guidelines Insights: Survivorship, Version 2.2020

Featured Updates to the NCCN Guidelines

Crystal S. Denlinger, Tara Sanft, Javid J. Moslehi, Linda Overholser, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Tracey O’Connor, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

NCCN Member Institutions (internal requests) or from outside individuals or groups (external requests). Among the changes the panel made this year were the addition of a new section on cardiovascular disease (CVD) risk assessment and changes to the